Cargando…
Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients
AIMS: Renin–angiotensin–aldosterone system (RAAS) inhibitors are well established for the reduction in cardiovascular morbidity, but their impact on all-cause mortality in hypertensive patients is uncertain. Our objective was to analyse the effects of RAAS inhibitors as a class of drugs, as well as...
Autores principales: | van Vark, Laura C., Bertrand, Michel, Akkerhuis, K. Martijn, Brugts, Jasper J., Fox, Kim, Mourad, Jean-Jacques, Boersma, Eric |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3418510/ https://www.ncbi.nlm.nih.gov/pubmed/22511654 http://dx.doi.org/10.1093/eurheartj/ehs075 |
Ejemplares similares
-
Influence of renin‐angiotensin‐aldosterone system inhibitors on plasma levels of angiotensin‐converting enzyme 2
por: Zimmermann, Tobias, et al.
Publicado: (2021) -
Renin‐angiotensin aldosterone profile before and after angiotensin‐converting enzyme‐inhibitor administration in dogs with angiotensin‐converting enzyme gene polymorphism
por: Adin, Darcy, et al.
Publicado: (2020) -
Individualized Angiotensin‐Converting Enzyme (ACE)‐Inhibitor Therapy in Stable Coronary Artery Disease Based on Clinical and Pharmacogenetic Determinants: The PERindopril GENEtic (PERGENE) Risk Model
por: Oemrawsingh, Rohit M., et al.
Publicado: (2016) -
Local Angiotensin-Converting Enzyme 2 Gene Expression in Kidney Allografts Is Not Affected by Renin-Angiotensin-Aldosterone Inhibitors
por: Cahova, Monika, et al.
Publicado: (2021) -
Renin-Angiotensin-Aldosterone Inhibitors and COVID-19
por: Benenson, Irina, et al.
Publicado: (2020)